Description

BSE announces the listing of 15,099,200 equity shares of Modern Diagnostic & Research Centre Limited with various lock-in periods.

Summary

BSE has listed 15,099,200 fully paid equity shares of Modern Diagnostic & Research Centre Limited in dematerialized form. The shares are subject to various lock-in periods ranging from February 2026 to January 2029, with the majority of securities locked until December 30, 2025.

Key Points

  • Total equity shares listed: 15,099,200
  • All securities are fully paid and in dematerialized form
  • Multiple tranches with distinctive number ranges from 1 to 15,099,200
  • Lock-in periods vary by tranche with expiry dates between January 2026 and January 2029
  • Initial lock-in date for most securities: December 30, 2025
  • Two tranches marked as “FREE” with lock-in expiry on January 5, 2026

Regulatory Changes

No regulatory changes announced. This is a standard listing notification.

Compliance Requirements

  • Securities are subject to lock-in restrictions as per SEBI regulations
  • All shares must remain in dematerialized form
  • Trading restrictions apply until respective lock-in expiry dates

Important Dates

  • December 30, 2025: Lock-in expiry for 12,161,600 shares (multiple tranches)
  • January 5, 2026: Lock-in expiry for 2,937,600 shares (two tranches marked “FREE”)
  • February 3, 2026: Lock-in expiry for 577,600 shares
  • April 4, 2026: Lock-in expiry for 584,000 shares
  • January 20, 2027: Lock-in expiry for 3,280,000 shares (three tranches)
  • January 20, 2028: Lock-in expiry for 5,445,000 shares (three tranches)
  • January 20, 2029: Lock-in expiry for 3,120,000 shares

Impact Assessment

This is a routine listing announcement with limited market impact. The staggered lock-in periods suggest a structured release of promoter or anchor investor holdings over a three-year period. The two “FREE” tranches totaling 2,937,600 shares (approximately 19.5% of total listed shares) will become tradable earliest on January 5, 2026. The phased unlock schedule may help manage supply and price stability in the secondary market.

Impact Justification

Routine listing announcement for a single company's equity shares with standard lock-in provisions